Table 1. Clinicopathologic Characteristics of Study Cohort.
| Characteristic | Patients (N = 500) |
|---|---|
| Age, median (IQR), y | 57 (48-69) |
| Sex, No. (%) | |
| Female | 487 (97.4) |
| Male | 13 (2.6) |
| Country, No. (%) | |
| Austria | 29 (5.8) |
| Germany | 31 (6.2) |
| Hungary | 99 (19.8) |
| Italy | 2 (0.4) |
| Lithuania | 4 (0.8) |
| Switzerland | 335 (67.0) |
| Menopausal status, No. (%) | |
| Postmenopausal | 342 (68.4) |
| Premenopausal | 157 (31.4) |
| Unknown | 1 (0.2) |
| Histological findings, No. (%) | |
| Ductal | 389 (77.8) |
| Lobular | 60 (12.0) |
| Other | 50 (10.0) |
| Unknown | 1 (0.2) |
| Differentiation, No. (%) | |
| Well | 32 (6.4) |
| Moderate | 294 (58.8) |
| Poor | 169 (33.8) |
| Unknown | 5 (1.0) |
| Receptor status, No. (%) | |
| HR−/ERBB2− | 35 (7.0) |
| HR−/ERBB2+ | 5 (1.0) |
| HR+/ERBB2− | 397 (79.4) |
| HR+/ERBB2+ | 52 (10.4) |
| Unknown | 11 (2.2) |
| Tumor size, median (IQR), mm | 28 (20-40) |
| Unknown | 17 |
| Breast surgery, No. (%) | |
| Breast-conserving surgery | 293 (58.6) |
| Mastectomy | 207 (41.4) |
| Treatment arm, No. (%) | |
| Arm A: ALND | 250 (50.0) |
| Arm B: no ALND | 250 (50.0) |
| No. of LNs retrieved during TAS, median (IQR) | 5 (3-8) |
| Unknown, No. | 7 |
| No. of additional LNs retrieved during ALND, median (IQR) | 12 (9-17) |
| Unknown, No. | 8 |
| Type of clinical node positivity, No. (%) | |
| Nonpalpable, detected by imaging | 242 (48.4) |
| Palpable | 258 (51.6) |
Abbreviations: ALND, axillary lymph node dissection; ERBB2−, Erb-B2 receptor tyrosine kinase 2 negative (formerly HER2 or HER2/neu); ERBB2+, Erb-B2 receptor tyrosine kinase 2 positive; HR−, hormone receptor negative; HR+, hormone receptor positive; TAS, tailored axillary surgery.